newsfilter
← Latest News
GlobeNewswire·

Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity

BOULDER, Colo., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("Fresh Tracks" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms